Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice
The primary objective of the study is to measure changes in physical functioning - serving as a surrogate for physical activity and exercise capacity - in COPD patients being treated with Spiolto® Respimat® after approximately 6…
- Trial name
- NCT02675517
- Testing
- Spiolto Respimat
- Where
- Germany
- Volunteers
- 1,737 people
- Sponsor
- Boehringer Ingelheim
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD
Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on…
- Conditions
- COVID-19, Chronic Bronchitis, Copd
- Trial name
- NCT05075057
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST1 (NCT00846586)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 137 sites in United States, Argentina and 10 more
- Volunteers
- 1,134 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Airway Disease
Clinical Study to Investigate Safety and Performance of NeuRx DPS in Patients Undergoing Bilateral Lung Transplantation
This study is a prospective, single-center feasibility study to acquire more knowledge regarding the NeuRx DPS and develop a routine in the optimal pacing of the diaphragm with this system during the weaning period from…
- Trial name
- NCT02411383
- Testing
- NeuRx Diaphragm Pacing System
- Where
- Belgium
- Volunteers
- 4 people
- Sponsor
- Synapse Biomedical
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
The purpose of this study is to prospectively evaluate the safety and efficacy of the AeriSeal System in patients with advanced Non-Upper Lobe Predominant Heterogeneous Emphysema.
- Trial name
- NCT01908933
- Testing
- AeriSeal Emphysematous Lung Sealant Syst
- Sponsor
- Aeris Therapeutics
Pulmonary Disease, Chronic Obstructive
Effects of Salmeterol on Autonomic Nervous System
This is a 4-week non-randomized, partially blinded, single-arm monocentre study in subjects with Chronic Obstructive Pulmonary Disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) class II or III with the…
- Trial name
- ESAN (NCT01536587)
- Testing
- Salmeterol
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Insomnia
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant (MK-4305) on respiratory function in participants with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01293006
- Testing
- suvorexant
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, Chronic Obstructive Pulmonary Disease
Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease
This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar…
- Trial name
- NCT05492448
- Testing
- L. salivarius AP-32 and L. reuteri GL-104, L. reuteri GL-104
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Glac Biotech Co., Ltd
Bronchitis, Chronic
Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD
Non-inferiority efficacy of telithromycin versus azithromycin
- Trial name
- NCT00538148
- Testing
- Telithromycin
- Volunteers
- 668 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe…
- Trial name
- TITANIA (NCT05158387)
- Testing
- Tozorakimab
- Where
- 212 sites in United States, Australia and 18 more
- Volunteers
- 1,172 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase IIa, open-label, repeat-dose trial to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide/Formoterol Fumarate 400/12 μg in 20 Chinese male…
- Trial name
- NCT03276078
- Testing
- Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
- Where
- China
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
COPD
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
- Trial name
- NCT07116915
- Testing
- HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension, Moxifloxacin Hydrochloride Tablets
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Chronic Obstructive Pulmonary Disease
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg
- Trial name
- NCT00669617
- Testing
- Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg)
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 89 people
- Sponsor
- Novartis
Emphysema or COPD
First in Human Study to Assess an Implant to Treat Severe Emphysema
The goal of this clinical trial is to test the feasibility of an implant for severe emphysema in up to 30 participants. The main questions it aims to answer are: Is it safe? Does it work? Participants who meet eligibility…
- Trial name
- BREATHE-1 (NCT05854550)
- Testing
- Apreo Implant Group
- Where
- 2 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Apreo Health, Inc.
Pulmonary Disease, Chronic Obstructive
Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate
dose-finding study to assess the optimal dose of glycopyrrolate daily dose on top of BDP/FF in COPD patients.
- Trial name
- NCT01476813
- Testing
- Glycopyrrolate, Comparator
- Where
- United Kingdom
- Volunteers
- 281 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
Prospective, multi-centre, non-interventional study to collect findings about the effects of LABA/LAMA (Long Acting Beta2-Agonists / Long Acting Muscarinic Antagonists) combination preparations on COPD (Chronic obstructive…
- Trial name
- DETECT (NCT02552160)
- Where
- 180 sites in Germany
- Volunteers
- 3,732 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This pharmacodynamic and pharmacokinetic dose-ranging study aims to determine the optimal dose of tiotropium inhaled as a solution from a Respimat device once a day for three weeks in patients with COPD.
- Trial name
- NCT02175342
- Testing
- Tiotropium 0.625 mcg/puff, Tiotropium 1.25 mcg/puff, Tiotropium 2.5 mcg/puff
- Volunteers
- 202 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD
Adherence Study in COPD Patients
A randomized clinical study to assess the impact of Symbicort® pMDI medication reminders on adherence in COPD patients
- Trial name
- NCT02864342
- Testing
- Arm 1: BreatheMate device with application, Arm 2: BreatheMate device without application
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation…
- Trial name
- NCT06748079
- Testing
- TQC3721 inhalation powder, TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
COPD
Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population
The DISCOVER TLD study is a multicenter, prospective, single-arm study designed to record the clinical outcomes of the CE-marked Nuvaira™ Lung Denervation System, in a subset of its CE-marked approved indication.
- Trial name
- DISCOVER TLD (NCT03213080)
- Testing
- Targeted Lung Denervation (TLD)
- Sponsor
- Nuvaira, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.